Minerva Neurosciences, Inc.
NERVAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 14, 2026 | Jefferies | Andrew Tsai | $10.00(+155%) | $3.92 | StreetInsider |
| Dec 1, 2025 | Jefferies | $5.00(+32%) | $3.80 | TheFly | |
| Aug 7, 2024 | H.C. Wainwright | Douglas Tsao | $5.00(+70%) | $2.94 | TheFly |
| May 2, 2024 | H.C. Wainwright | Douglas Tsao | $7.00(+192%) | $2.40 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Jefferies | upgrade | Hold →Buy | Aug 14, 2026 |
| HC Wainwright & Co. | maintain | Neutral | Mar 12, 2026 |
| HC Wainwright & Co. | maintain | Neutral | Nov 6, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Feb 26, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Nov 6, 2024 |
| HC Wainwright & Co. | maintain | Neutral | Aug 7, 2024 |
| HC Wainwright & Co. | maintain | Neutral | May 2, 2024 |
| HC Wainwright & Co. | maintain | Neutral | Feb 27, 2024 |
| HC Wainwright & Co. | maintain | Neutral | Aug 2, 2023 |
| HC Wainwright & Co. | maintain | Neutral | May 16, 2023 |
| HC Wainwright & Co. | maintain | Neutral | May 2, 2023 |
| HC Wainwright & Co. | maintain | Neutral | Mar 9, 2023 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Nov 10, 2022 |
| JMP Securities | downgrade | Market Outperform →Market Perform | Oct 17, 2022 |
| HC Wainwright & Co. | maintain | Buy | Mar 4, 2022 |
| HC Wainwright & Co. | maintain | Buy | Jun 8, 2020 |
| JMP Securities | maintain | Market Outperform | Dec 19, 2019 |
| H.C. Wainwright | maintain | Buy | Dec 19, 2019 |
| Chardan Capital | maintain | Buy | Sep 25, 2019 |
| William Blair | maintain | Outperform | Sep 18, 2019 |
| H.C. Wainwright | maintain | Buy | May 31, 2019 |
| Jefferies | maintain | Buy | Mar 6, 2017 |
| Jefferies | maintain | Buy | May 27, 2016 |
| JMP Securities | maintain | Market Outperform | Mar 9, 2016 |
| JMP Securities | maintain | Market Perform →Perform | Jul 28, 2014 |
Earnings History
Next report: Mar 10, 2027 · EPS est. $-0.09| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 6, 2026 | $-1.60 | $-0.14 | — | — |
| Aug 7, 2026 | $-0.14 | $-0.19 | — | — |
| May 5, 2026 | $-2.86 | $-0.13 | — | — |
| Mar 11, 2026 | $-0.64 | $-0.11 | — | — |
| Nov 5, 2025 | $-0.36 | $-0.35 | — | — |
| Aug 14, 2025 | $-0.43 | $-0.95 | — | — |
| May 13, 2025 | $-0.50 | $-1.07 | — | — |
| Feb 25, 2025 | $-0.56 | $-1.05 | $42.2K | — |
News
Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027
BURLINGTON, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that management will participate in the 2026 Jefferies Global Healthcare Conference in London.
BURLINGTON, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it will host an in-person and virtual event in New York on Thursday, November 12, 2026, at 10:00 AM ET featuring several key opinion leaders and company management focused on the opportunity for roluperidone in treating the negative symptoms of schizophren…
BURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that management will participate in two upcoming investor conferences.
Minerva Neurosciences, Inc (NASDAQ: NERV - Get Free Report) has been assigned an average rating of "Reduce" from the four brokerages that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and one has given a buy recommendation to the company.